

SCHEDULE 3

Consequential Amendments

National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013

9. In regulation 2(1) (interpretation) of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 ^{M1}—

- (a) for the definition of “advanced electronic signature”, substitute—
- ““advanced electronic signature” means an electronic signature which meets the following requirements—
- (a) it is uniquely linked to the signatory;
 - (b) it is capable of identifying the signatory;
 - (c) it is created using electronic signature creation data that the signatory can, with a high level of confidence, use under the signatory's sole control; and
 - (d) it is linked to the data signed in such a way that any subsequent change in the data is detectable;”;
- (b) after the definition “electronic repeatable prescription”, insert—
- ““electronic signature” means data in electronic form which is attached to or logically associated with other data in electronic form and which is used by the signatory to sign;
- “electronic signature creation data” means unique data which is used by the signatory to create an electronic signature;”;
- (c) after the definition “scheme premises” insert—
- ““signatory” means a natural person who creates an electronic signature;”.

Marginal Citations

M1 S.I. 2013/349, to which there are amendments not relevant to these Regulations.

Changes to legislation:

There are currently no known outstanding effects for the The Electronic Identification and Trust Services for Electronic Transactions Regulations 2016, Paragraph 9.